UBS/CALL/IDORSIA/22.008/0.125/21.06.24 Stock

Warrant

LIDIEU

CH1243314809

Market Closed - Swiss Exchange 11:20:00 2023-06-29 am EDT
0.02 ^CHF	-33.33%

3 months

-77.78%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart IDORSIA LTD

Chart UBS/CALL/IDORSIA/22.008/0.125/21.06.24

Latest news about IDORSIA LTD

Data from the PRECISION study of aprocitentan to be presented at the European Society of Hypertension Annual Meeting 2024	May. 31	GL
Idorsia : Invitation to the AGM 2024	May. 23	PU
Idorsia : Supplement to the invitation to the AGM 2024	May. 23	PU
Idorsia issues invitation to the 2024 Annual General Meeting of Shareholders	May. 23	GL

More news

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	IDORSIA LTD
Issuer	UBS
	LIDIEU
ISIN	CH1243314809
Date issued	2023-01-16
Strike	22.01 CHF
Maturity	2024-06-21 (20 Days)
Parity	8 : 1
Emission price	0.32 CHF
Emission volume	N/A
Settlement	physical
Currency	CHF

Technical Indicators

Highest since issue	0.37 CHF
Lowest since issue	0.02 CHF

Company Profile

Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.

Sector

More about the company